Xcell Initiates New Collaborations with UCSF Researchers
News Sep 23, 2016
Xcell Biosciences has announced that it has extended its collaborative work with the University of California, San Francisco (UCSF) to include working with three principal investigators on pilot studies using Xcell’s Avatar cell culture system and proprietary analytics platform. The work will determine if large scale RNA profiling from peripheral blood and other patient-derived sample sources cultured in the Avatar System and correlated to clinical outcomes can predict a patient’s response to first or second line treatments in prostate, bladder and kidney cancers.
Charles J. Ryan, MD, Professor of Clinical Medicine and Urology and the Clinical Program Leader for Genitourinary Medical Oncology at the UCSF Helen Diller Family Comprehensive Cancer Center, has been collaborating with Xcell for several years on a number of projects. The latest involves studying the relationship between genomic variation in prostate cancer patient samples and response to treatment, including in patients who have developed resistance to standard of care therapies.
“We are particularly enthusiastic about the opportunity to use the Avatar system to compare results from liquid biopsies to actual tissue biopsies,” said Dr. Ryan. “We also are optimistic about the ability to use the system to look at broad-scale genomic alterations in cancer patients without the necessity for looking at circulating tumor cells, cell free DNA or tissue biopsies. Xcell’s system offers the opportunity to look at different types of analysis all with one blood draw – for example, potential relationships between immunology, androgen receptors, and DNA repair in prostate cancer.”
Terry Friedlander, MD, Associate Clinical Professor of Medicine at UCSF, is collaborating on studies involving prostate and bladder cancer. “We are excited about this collaboration and the potential ability to use the Avatar system as an immunologic springboard,” he said. “Predicting treatment response is a huge unanswered question in oncology in general. If the Avatar system can keep the cells in the same state that they were in the body, we may get a more accurate read on the activation status of the immune system and determine markers that might help predict response to treatment.”
UCSF medical oncologist Won Kim, MD, who is leading a study in kidney cancer, added: “Kidney cancer is a disease where we have a real shortage of predictive and prognostic biomarkers. For this pilot study, we’re hopeful that we will show that the data generated from Xcell’s platform will help us identify which patients with renal cell cancer are more likely to respond to tyrosine kinase inhibitors or immunotherapy. We all want these feasibility studies to succeed because there are so many cancers where tissue is just not easy to access.”
James Lim, PhD, Chief Scientific Officer at Xcell Biosciences, commented, “We are delighted to continue our collaborative work with UCSF, a leading center for cancer clinical research, on these new studies. We believe our RNA-based whole transcriptome approach to liquid biopsy will enable us to generate unique gene expression signatures that will predict a patient’s response to a given therapeutic. Our goal is to ultimately demonstrate evidence that the Avatar system’s physiologically relevant microenvironments can provide unparalleled and previously unavailable diagnostic insights enabling oncologists to treat patients more effectively and also at the right time.”
Early Life Experiences Alter DNA Structure in the Adult BrainNews
Scientists report in the journal Science that the type of mothering a female mouse provides her pups actually changes their DNA.READ MORE
Stem Cells in Menstrual Blood Could Help Diagnose EndometriosisNews
The Feinstein Institute for Medical Research scientists announced an experimental, rapid and non-invasive way to diagnose endometriosis, which may lead to earlier and more effective treatments for this disorder that affects approximately 176 million women globally.READ MORE
SMi’s 5th Annual Molecular Diagnostics Conference 2018 Agenda ReleasedNews
SMi proudly presents its 5th annual conference on Molecular Diagnostics, taking place at the Holiday Inn Kensington Forum, London, UK on 9th and 10th July 2018, with a half-day post-conference workshops on 11th July 2018.READ MORE